Pros and cons of critical pathways for improving healthcare Newsletter Article 08 February 2013 Pages: 2 - 2
Less harmful drugs needed to contain escalating cancer costs Newsletter Article 08 February 2013 Pages: 2 - 2
How do customers judge the quality of pharmacoeconomic studies? Tracey Langsdale Newsletter Article 08 February 2013 Pages: 3 - 4
Challenges of performing economic analyses of AIDS therapies Newsletter Article 08 February 2013 Pages: 4 - 4
Irritable bowel syndrome not life-threatening but costly Newsletter Article 08 February 2013 Pages: 5 - 5
Comparing costs of 3 oral antifungals in severe tinea Newsletter Article 08 February 2013 Pages: 5 - 5
Is nefazodone cost effective vs other antidepressants? Newsletter Article 08 February 2013 Pages: 6 - 6
Amoxicillin/clavulanic acid ‘superior’ in community-acquired pneumonia Newsletter Article 08 February 2013 Pages: 6 - 6
Symptom checklists vital for comprehensive QOL assessment Newsletter Article 08 February 2013 Pages: 6 - 7